Pasar al contenido principal

LAM226 en el tratamiento de neuropatías: Desarrollo preclínico y nuevos candidatos. (NEUROPAT226)

CPP2021-008855

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Transferencia de Conocimiento
Convocatoria Proyectos en Colaboración Público-Privada
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario LAMINAR PHARMACEUTICALS SA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Neuroprotective effects of meloxicam on transient brain ischemia in rats: the two faces of anti-inflammatory treatments

  • Fernández Ugidos, Irene
  • González Rodríguez, Paloma
  • Santos Galdiano, María
  • Font Belmonte, Enrique
  • Anuncibay Soto, Berta
  • Pérez Rodríguez, Diego
  • Gonzalo Orden, José Manuel
  • Fernández López, Arsenio
[EN] The inflammatory response plays an important role in neuroprotection and regeneration after ischemic insult. The use of non-steroidal anti-inflammatory drugs has been a matter of debate as to whether they have beneficial or detrimental effects. In this context, the effects of the anti-inflammatory agent meloxicam have been scarcely documented after stroke, but its ability to inhibit both cyclooxygenase isoforms (1 and 2) could be a promising strategy to modulate post-ischemic inflammation. This study analyzed the effect of meloxicam in a transient focal cerebral ischemia model in rats, measuring its neuroprotective effect after 48 hours and 7 days of reperfusion and the effects of the treatment on the glial scar and regenerative events such as the generation of new progenitors in the subventricular zone and axonal sprouting at the edge of the damaged area. We show that meloxicam's neuroprotective effects remained after 7 days of reperfusion even if its administration was restricted to the two first days after ischemia. Moreover, meloxicam treatment modulated glial scar reactivity, which matched with an increase in axonal sprouting. However, this treatment decreased the formation of neuronal progenitor cells. This study discusses the dual role of anti-inflammatory treatments after stroke and encourages the careful analysis of both the neuroprotective and the regenerative effects in preclinical studies, SI, This work was supported by MINECO and FEDER funds: ref CPP2021-008855 and RTC-2015-4094-1, Junta de Castilla y León ref. LE025P17, and Neural Therapies SL, ref. NT-Dev-01 (all to AFL and JMGO).
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Critical ischemia duration thresholds in the rat middle cerebral artery occlusion model: Implications for drug screening

  • Puente Sanz, Alba
  • Herrero González, Amanda
  • Pérez Rodríguez, Diego
  • Gonzalo Orden, José Manuel
  • Letek Polberg, Michal
  • Anuncibay Soto, Berta
  • Fernández López, Arsenio
Es un artículo de publicación anticipada, aunque ya tiene asignado el volumen (21) y un número de artículo (1059), el número específico de la edición mensual todavía no ha sido determinado, [EN] The growing incidence of stroke and the absence of drugs to fight its devastating consequences highlight the urgent need to identify therapeutic agents. The middle cerebral artery occlusion model is commonly used to screen new putative anti-stroke agents in rodents. However, differences in ischemia and reperfusion times result in differences in neurological deficit and infarct volume, two of the most commonly used parameters in preclinical assays. These differences make it difficult to select the optimal screening conditions. Here, we report a parallel study comparing behavior, infarct volume, and transcriptomic outcomes after 15 days of reperfusion in a rat middle cerebral artery occlusion model with mild (45 minutes) and moderate (60 minutes) ischemia. The behavioral assays revealed that motor and sensory responses, but not the infarct volume, are sensitive to slight variations in the time of ischemia. The transcriptomic profiling demonstrated striking changes in the number of up- and downregulated genes between mild and moderate ischemia. Gene Ontology analysis supported noteworthy differences between mild and moderate ischemia, particularly in genes related to protein synthesis and processing. Complementary quantitative polymerase chain reaction and western blotting assays confirmed these differences. These results indicate a threshold between mild and moderate ischemia, where changes in behavior and molecular responses mirror a substantial alteration in brain cell biology that appears critical for molecular screening. These findings pinpoint the critical role of selecting the appropriate ischemia model in preclinical stroke studies to enhance the translational relevance of the results and therapeutic strategies, SI, Funding: Project with Ref. CPP2021-008855 was funded by MICIU/AEI/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. AHG and APS were partially granted by Ministerio de Innovación, Ciencia y Universidades, fellowships DIN2019-010525 and DIN2018-010144, respectively, and by Neural Therapies S.L